Cargando…

An Assessment of Combination of the Camrelizumab With Chemotherapy in Metastatic Biliary Tract Cancers

BACKGROUND: Monoclonal antibodies that target the PD-1 receptor are emerging as promising therapeutic candidates for the treatment of biliary tract cancers (BTCs). The purpose of the current study was to assess the combination of the camrelizumab with chemotherapy as a first-line treatment for metas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Yi, Huang, Shanshan, Chen, Jun, Yu, Feng, Zhang, Lin, Xiang, Xiaojun, Deng, Jun, Fang, Ziling, Li, Junhe, Xiong, Jianping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204626/ https://www.ncbi.nlm.nih.gov/pubmed/33982628 http://dx.doi.org/10.1177/10732748211017165

Ejemplares similares

Ruscogenin induces ferroptosis in pancreatic cancer cells
por: Song, Zhiwang, et al.
Publicado: (2020)

Aortic dissection in a patient treated with anlotinib for metastatic lung squamous cell carcinoma
por: Jiang, Bailing, et al.
Publicado: (2019)

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review
por: Shen, Tian, et al.
Publicado: (2020)

NUSAP1 Promotes Gastric Cancer Tumorigenesis and Progression by Stabilizing the YAP1 Protein
por: Guo, Hui, et al.
Publicado: (2021)

Corrigendum: NUSAP1 Promotes Gastric Cancer Tumorigenesis and Progression by Stabilizing the YAP1 Protein
por: Guo, Hui, et al.
Publicado: (2021)

Immuno-genomic-radiomics to predict response of biliary tract cancer to camrelizumab plus GEMOX in a single-arm phase II trial
por: Liu, Qiu-Ping, et al.
Publicado: (2023)

Follistatin-like 1 (FSTL1) is a prognostic biomarker and correlated with immune cell infiltration in gastric cancer
por: Li, Li, et al.
Publicado: (2020)

The microRNA-381(miR-381)/Spindlin1(SPIN1) axis contributes to cell proliferation and invasion of colorectal cancer cells by regulating the Wnt/β-catenin pathway
por: Zhou, Ling, et al.
Publicado: (2021)

Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy
por: Qiao, Yujin, et al.
Publicado: (2022)

miR‐3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi‐targets
por: Zhou, Ling, et al.
Publicado: (2023)

Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study)
por: Yang, Yunpeng, et al.
Publicado: (2021)

miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3
por: Chen, Jun, et al.
Publicado: (2018)

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study
por: Wang, Dongxu, et al.
Publicado: (2021)

Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial
por: Chen, Xiaofeng, et al.
Publicado: (2020)

Up‐regulated acylglycerol kinase (AGK) expression associates with gastric cancer progression through the formation of a novel YAP1‐AGK–positive loop
por: Huang, Shanshan, et al.
Publicado: (2020)

Down‐regulation of interferon regulatory factor 2 binding protein 2 suppresses gastric cancer progression by negatively regulating connective tissue growth factor
por: Yao, Yangyang, et al.
Publicado: (2019)

Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma
por: Guo, Yusheng, et al.
Publicado: (2022)

Chemotherapy for Biliary Tract Cancer in 2021
por: Sasaki, Takashi, et al.
Publicado: (2021)

Successful response to camrelizumab in metastatic bladder cancer: A case report
por: Xie, Chen, et al.
Publicado: (2022)

Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial
por: Li, Jian-Xu, et al.
Publicado: (2022)

Guidelines for chemotherapy of biliary tract and ampullary carcinomas
por: Furuse, Junji, et al.
Publicado: (2008)

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma
por: Zhang, Bo, et al.
Publicado: (2020)

Clinical Complete Remission of An Advanced Gastric Adenocarcinoma After Camrelizumab Plus Chemotherapy Followed by Camrelizumab Plus Capecitabine: A Case Report
por: Lin, Jieheng, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Camrelizumab Versus Chemotherapy as Second-Line Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Cai, Hongfu, et al.
Publicado: (2021)

LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma
por: Huang, Shanshan, et al.
Publicado: (2021)

Camrelizumab Plus Apatinib in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma: An Open-Label, Single-Arm, Phase II Study
por: Ding, Xi, et al.
Publicado: (2023)

Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports
por: Tian, Yuan, et al.
Publicado: (2023)

Three-arm phase II trial comparing camrelizumab plus chemotherapy versus camrelizumab plus chemoradiation versus chemoradiation as preoperative treatment for locally advanced esophageal squamous cell carcinoma (NICE-2 Study)
por: Yang, Yang, et al.
Publicado: (2022)

Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer
por: Sun, Danyang, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
por: Lin, Ying-Tao, et al.
Publicado: (2021)

Efficacy and safety of nivolumab for metastatic biliary tract cancer
por: Gou, Miaomiao, et al.
Publicado: (2019)

Hepatectomy combined with apatinib and camrelizumab for CNLC stage IIIb hepatocellular carcinoma: a phase II trial protocol
por: Huang, Jun Tao, et al.
Publicado: (2023)

Adjuvant Radio-chemotherapy for extrahepatic biliary tract cancers
por: Bonet Beltrán, Marta, et al.
Publicado: (2011)

Current progress in perioperative chemotherapy for biliary tract cancer
por: Ioka, Tatsuya, et al.
Publicado: (2023)

M1 macrophage predicted efficacy of neoadjuvant camrelizumab combined with chemotherapy vs chemotherapy alone for locally advanced ESCC: A pilot study
por: Wang, Shu, et al.
Publicado: (2023)

Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors
por: Zhang, Zhengfeng, et al.
Publicado: (2023)

Neoadjuvant camrelizumab plus chemotherapy in locally advanced oesophageal squamous cell carcinoma: a retrospective cohort study
por: Zhou, Rui-Qin, et al.
Publicado: (2023)

Regulation of TRIM24 by miR-511 modulates cell proliferation in gastric cancer
por: Fang, Ziling, et al.
Publicado: (2017)

Cost-effectiveness analysis of pembrolizumab in combination with chemotherapy compared with chemotherapy alone as first-line treatment for patients with advanced biliary tract cancer in China
por: Zheng, Zhiwei, et al.
Publicado: (2023)

Cullin 4A (CUL4A), a direct target of miR-9 and miR-137, promotes gastric cancer proliferation and invasion by regulating the Hippo signaling pathway
por: Deng, Jun, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b4ulnm1pk0l8dbpfd3b18crk0c